Anti-CD8 [14] mAb
Exclusive ToolClone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis.
Contributors
| Inventor | Institute |
|---|---|
| Nancy Hogg | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| SKU: | 151035 |
|---|---|
| Product description: | Clone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis. |
| Alternate name: | Leu2 |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Fibronectin-purified human monocytes |
| Myeloma used: | Sp2/0-Ag14 |
| Cat. #: | 151035 |
|---|---|
| Provenance and Ownership: | The Anti-CD8 14 mAb is owned by Cancer Research UK. CancerTools supplies the Anti-CD8 14 mAb under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-CD8 14 mAb directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer; Immunology; Stem cell biology |
| Application: | ELISA ; FACS ; IHC ; IP |
| Target: | CD8 |
| Reactivity: | Human |
| Clone: | 14 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | CD8 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. CD8 is present on human suppressor / cytotoxic T cells, 30% of circulating T cells. Clone 14 is recommended for: the detection of immunoregulatory T cell subset imbalances in autoimmune disorders and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma in conjunction with other antigens and determination of CD4/CD8 ratios in immune deficiencies, rheumatoid arthritis and multiple sclerosis. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Hogg et al. 1999. J Clin Invest. 103(1):97-106. PMID: 9884339. |
|---|
Images
View Gallery
Product Images
77e9ad03-183d-49a7-b369-ede38204fee5.png
Adapted from Xiao F; Ma L; Zhao M; Huang G; Mirenda V; Dorling A; Lechler R; Lombardi G. Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2r?null mice. PLoS One. 2014 Mar 3;9(3)
